The latest edition of Nightwalkers, the US RLS foundation magazine, reports that Prof. Stefan Clemens of East Carolina University has applied for a patent to use Ecopipam to treat augmentation of RLS symptoms on dopaminergic drugs.
He has licensed the product to Emalax Biosciences and trials will happen soon.
Dopaminergic drugs affect the D2 and D3 dopamine receptors and stop them being over excited. However, over time the D1 receptors then become over excited and cause augmentation ( worsening of symptoms). Ecopipam targets the D1 receptors and calms them, apparently alleviating augmentation.
It is early days, but if Ecopipam does indeed work to stop augmentation, it would be life changing for RLS patients.
There are so few research studies or trials of new medications so this is encouraging.